TELA Bio, Inc. (TELA): Nasdaq/NYSE listing notice — TELA Bio receives Nasdaq deficiency notice for bid price below $1.00

TELA Bio, Inc.

Nasdaq notified TELA on March 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.
Company has until September 14, 2026 to regain compliance by closing at $1.00 for 10 consecutive days.
Stock continues trading on Nasdaq Global Market under symbol TELA; no immediate delisting effect.
If not cured by September 14, TELA may transfer to Nasdaq Capital Market for a second 180-day cure period.
Company says it will monitor bid price and consider options to regain compliance; no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TELA Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“ Rule 5450(a)(1) ”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock

View on SEC.gov

Browse all listing & compliance notices →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-032697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.